Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
PMSL :-)
Bottmzup 19:25
"expect a dip to around 112p ??
Well if it dips to 112p then I wouldn't be surprised if it doesn't rise again until after it has closed the gap (on the 4 hour chart) at c108p!
Still in the current short term falling trend so who knows how low it will go.
Tomorrow is the last trading day before the results so expecting a few more sellers taking recent profits off the table...for uncertainty reasons.
Or just stop losses getting triggered as the sp trickles lower.
I'll be waiting for a nice re-entry price! "
Thornogson "Back in 2020 all things "seamed" possible, indeed probable"
So looks like we have all be stitched up :-)
Sorry Thorn couldn't resist and I know your spell check is responsible.....been there done that :-)
100% Bella.....income v debt, at the minute AVCT income is not exactly well known. However, that will soon change and until it does people can speculate as much or as little as they like, it won't make the difference we all want and expect.
Richar, step away from the keyboard and pay close attention to your minder (that’s the guy in the white coat) when he offers you your pills take them as advised and don’t struggle when two additional minders appear with your straight jacket. All will be well when your medication kicks in.
"A bio tech originating in Yorkshire trialing chemo without side effects has to go to the US to really push it forward. That's a sad state of affairs for the UK"
It's actually pathetic Timster, unfortunately Joe public can do nothing about it as it all falls on corrupt useless politicians who only care about one thing....themselves.
I'm the first to admit I make mistakes but this is a classic :-), BITL is undoubtedly a valued educated poster but a little less of my opinion and my opinion only from time to time would probably be appreciated.
beinthelead
Posts: 3,599
Price: 104.00
No Opinion
RE: 'Completion of C6' RNS tomorrow...6 Sep 2023 17:37
Never has there been any news or update aligned to one of these presentations. In fact, every single presentation has been the catalyst for a drop in the SP. Go figure. So, as always, be careful what you wish for. Or in this case, dream up.
Cohort completion or not, it won’t make any odds. We won’t get anymore info. It’ll be ‘excellent’, ‘very pleased’ at best.
Oh and BTW Ophidian you have your head shoved so far up your own a.r.s.e I'm amazed you can actually see in order to actually type a message on this board.
The statement below IMO says it all, the FDA are going to be all over this, fast tracking through the various hoops and hopefully significant funding granted.
"Therefore, in parallel with the completion of cohort 7, the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA)"
Donkeyeeyore, you have echoed my thoughts. Avacta have previously been very spectacularly caught out. They now make a point of no boosting, in my opinion they now don't need to and they full well know it. Anyway, that's what I'm sticking to and hopefully I am right, if I'm wrong it's only money. Have a great weekend folks and ignore the FUD. Hope you are correct LDA :-)
@Ianbt "if you’re trying to identify an idiot, get yourself" lessons on how to use capital letters at the start of a sentence, that'll do just for starters.
Oh....and BTW, get yourself a mirror to remind yourself on a regular basis why you are actually attending the lessons :-)
PL75, I also should have suggested you read Icecools posts and then have a look at the reply you sent to me.....perhaps you struggle with that. It's blatantly obvious you have a major bee in your bonnet with Icecool, just get over it hun :-)